Comparison of a point-of-care test for high-sensitivity C-reactive protein with an established immuno-nephelometric method

Clinical Laboratory

Volumn 61, Issue 10, 2015, Pages 1585-1588

  Markovic, Sinisa ^a   Armbruster, Franz Paul ^b   Dschietzig, Thomas Bernd ^b,c   Koenig, Wolfgang ^a  

^a UNIVERSITY HOSPITAL ULM   (Germany)

^b IMMUNDIAGNOSTIK AG   (Germany)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Arteriosclerosis; C reactive protein; Point of care test

Indexed keywords

C REACTIVE PROTEIN;

ARTICLE; CARDIOVASCULAR RISK; DIAGNOSTIC TEST ACCURACY STUDY; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; NEPHELOMETRY; POINT OF CARE TESTING; PREDICTIVE VALUE; SENSITIVITY AND SPECIFICITY; BLOOD; CARDIOVASCULAR DISEASES; CHEMISTRY; CLINICAL CHEMISTRY; COMPARATIVE STUDY; FEMALE; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHOTOMETRY; RISK FACTOR;

C-REACTIVE PROTEIN; CARDIOVASCULAR DISEASES; CHEMISTRY, CLINICAL; DIABETES MELLITUS, TYPE 2; FEMALE; HUMANS; MALE; NEPHELOMETRY AND TURBIDIMETRY; POINT-OF-CARE TESTING; PREDICTIVE VALUE OF TESTS; RISK FACTORS; SENSITIVITY AND SPECIFICITY;

EID: 84948430389     PISSN: 14336510     EISSN: None     Source Type: Journal    
DOI: 10.7754/Clin.Lab.2015.141108     Document Type: Article

References (23)

1. Bassuk SS, Rifai N, Ridker PM High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 2004; 29:439-93.
2. Willerson JT. Systemic and local inflammation in patients with unstable atherosclerotic plaques. Prog Cardiovasc Dis 2002; 44: 469-78.
3. Wilson PW, Castelli WP, Kannel WB Coronary risk prediction in adults (the Framingham Heart Study). Am J Cardiol 1987; 59: 91G-4G.
4. Ridker PM, Cushman M, Stampfer M.J., Tracy RP, Hennekens CH. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. N Engl J Med 1997; 336:973-9.
5. Ridker PM, Hennekens CH, Buring J.E., Rifai N. C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women. N Engl J Med 2000; 342:836-43.
6. Koenig W, Sund M, Frohlich M., et al. C-Reactive protein, a sensitive marker of inflammation, predicts future risk of coronary heart disease in initially healthy middle-aged men: results from the MONICA (Monitoring Trends and Determinants in Cardiovascular Disease) Augsburg Cohort Study, 1984 to 1992. Circulation 1999; 99:237-42.
7. Boekholdt SM, Sandhu MS, Day N.E., et al. Physical activity, Creactive protein levels and the risk of future coronary artery disease in apparently healthy men and women: the EPIC-Norfolk prospective population study. Eur J Cardiovasc Prev Rehabil 2006; 13:970-6.
8. Ridker PM, Buring JE, Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulation 2003; 107:391-7.
9. Kaptoge S, Di AE, Penneils L, et al C-reactive protein, fibrinogen, and cardiovascular disease prediction. N Engl J Med 2012; 367:1310-20.
10. Perk J, De Backer BG, Gohlke H, et al. European Guidelines on cardiovascular disease prevention in clinical practice (version 2012). The Fifth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of nine societies and by invited experts). Eur Heart J 2012; 33:1635-701.
11. Goff DC, Jr., Lloyd-Jones DM, Bennett G, et al. 2013 ACC/AHA guideline on the assessment of cardiovascular risk: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2014; 63: 2935-59.
12. Ridker PM, Danielson E, Fonseca F.A., et al. Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med 2008; 359:2195-207.
13. Hutchinson WL, Koenig W, Frohlich M., Sund M, Lowe GD, Pepys MB Immunoradiometric assay of circulating C-reactive protein: age-related values in the adult general population. Clin Chem 2000; 46:934-8.
14. Rifai N, Tracy RP, Ridker PM Clinical efficacy of an automated high-sensitivity C-reactive protein assay. Clin Chem 1999; 45: 2136-41.
15. Roberts WL, Moulton L, Law T.C., et al. Evaluation of nine automated high-sensitivity C-reactive protein methods: implications for clinical and epidemiological applications. Part 2. Clin Chem 2001; 47:418-25.
16. Khuseyinova N, Imhof A, Trischler G., et al. Determination of Creactive protein: comparison of three high-sensitivity immunoassays. Clin Chem 2003; 49:1691-5.
17. Papaevangelou V, Papassotiriou I, Sakou I., et al. Evaluation of a quick test for C-reactive protein in a pediatric emergency department. Scand J Clin Lab Invest 2006; 66:717-21.
18. Seamark DA, Backhouse SN, Powell R. Field-testing and validation in a primary care setting of a point-of-care test for C-reactive protein. Ann Clin Biochem 2003; 40:178-80.
19. Siebenhaar R, Mushholt PB, Forst T, Weber M.M., Maurer R., Pfiitzner A. Laboratory evaluation of a new lateral-flow-based point-of-care rapid test for assessment of chronic systemic inflammation. J Diabetes Sci Technol 2010; 4:717-22.
20. Zecca E, Barone G, Corsello M., et al. Reliability of two different bedside assays for C-reactive protein in newborn infants. Clin Chem Lab Med 2009; 47:1081-4.
21. Pepys MB, Hirschfield GM C-reactive protein: a critical update. J Clin Invest 2003; 111:1805-12.
22. Ahn JS, Choi S, Jang S.H., et al. Development of a point-of-care assay system for high-sensitivity C-reactive protein in whole blood. Clin Chim Acta 2003; 332:51-9.
23. Oh SW, Moon JD, Park S.Y., et al. Evaluation of fluorescence hs-CRP immunoassay for point-of-care testing. Clin Chim Acta 2005; 356:172-7.